FI942905A - Stabiloitu kasvuhormonia ja asparagiinia sisältävä farmaseuttinen formulointi - Google Patents

Stabiloitu kasvuhormonia ja asparagiinia sisältävä farmaseuttinen formulointi Download PDF

Info

Publication number
FI942905A
FI942905A FI942905A FI942905A FI942905A FI 942905 A FI942905 A FI 942905A FI 942905 A FI942905 A FI 942905A FI 942905 A FI942905 A FI 942905A FI 942905 A FI942905 A FI 942905A
Authority
FI
Finland
Prior art keywords
growth hormone
asparagine
pharmaceutical formulation
formulation containing
containing growth
Prior art date
Application number
FI942905A
Other languages
English (en)
Swedish (sv)
Other versions
FI942905A0 (fi
Inventor
Hans Holmegaard Soerensen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of FI942905A publication Critical patent/FI942905A/fi
Publication of FI942905A0 publication Critical patent/FI942905A0/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI942905A 1991-12-20 1994-06-17 Stabiloitu kasvuhormonia ja asparagiinia sisältävä farmaseuttinen formulointi FI942905A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK912047A DK204791D0 (da) 1991-12-20 1991-12-20 Hidtil ukendt farmaceutisk praeparat
PCT/DK1992/000378 WO1993012811A1 (en) 1991-12-20 1992-12-16 A stabilized pharmaceutical formulation comprising growth hormone and asparagine

Publications (2)

Publication Number Publication Date
FI942905A true FI942905A (fi) 1994-06-17
FI942905A0 FI942905A0 (fi) 1994-06-17

Family

ID=8109696

Family Applications (1)

Application Number Title Priority Date Filing Date
FI942905A FI942905A0 (fi) 1991-12-20 1994-06-17 Stabiloitu kasvuhormonia ja asparagiinia sisältävä farmaseuttinen formulointi

Country Status (19)

Country Link
US (2) US5977069A (fi)
EP (1) EP0618806B1 (fi)
JP (1) JP3662580B2 (fi)
KR (1) KR100270726B1 (fi)
AT (1) ATE177645T1 (fi)
AU (1) AU664416B2 (fi)
BG (1) BG98804A (fi)
CA (1) CA2125856A1 (fi)
CZ (1) CZ282826B6 (fi)
DE (1) DE69228704T2 (fi)
DK (1) DK204791D0 (fi)
FI (1) FI942905A0 (fi)
HU (1) HUT69682A (fi)
NO (1) NO942299D0 (fi)
NZ (1) NZ246555A (fi)
RO (1) RO112086B1 (fi)
RU (1) RU2098130C1 (fi)
SK (1) SK73794A3 (fi)
WO (1) WO1993012811A1 (fi)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
US5652216A (en) * 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
ZA96122B (en) * 1995-01-13 1996-07-24 Novo Nordisk As A pharmaceutical formulation
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
WO1996021460A1 (en) * 1995-01-13 1996-07-18 Novo Nordisk A/S A stabilized pharmaceutical formulation comprising a growth hormone and x-lys
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
ZA965367B (en) * 1995-07-12 1997-01-23 Novo Nordisk As A pharmaceutical formulation
WO1997007794A1 (fr) * 1995-08-28 1997-03-06 Showa Yakuhin Kako Co., Ltd. Composition pour anesthesie locale
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
EP1309312A2 (en) * 2000-08-07 2003-05-14 Inhale Therapeutic Systems, Inc. Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
WO2002092619A2 (en) * 2001-05-14 2002-11-21 The Gouvernment Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
RU2234945C2 (ru) * 2002-10-15 2004-08-27 Вардосанидзе Ирина Викторовна Стабилизатор водного раствора и водосодержащего сырья с самопроизвольно изменяющимися окислительно-восстановительными свойствами
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US20080213377A1 (en) * 2006-12-08 2008-09-04 Bhatia Sangeeta N Delivery of Nanoparticles and/or Agents to Cells
US20160015789A1 (en) * 2014-07-17 2016-01-21 Teva Pharmaceutical Industries, Ltd. FORMULATIONS OF AN ALBUMIN hGH FUSION PROTEIN

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
EP0303746B2 (en) * 1987-08-21 1998-12-02 Mallinckrodt Group Inc. Stabilization of growth promoting hormones
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5122512A (en) * 1988-09-12 1992-06-16 Pitman-Moore, Inc. Swine growth promoting composition
EP0374120A3 (en) * 1988-12-13 1991-07-31 Monsanto Company Comosition for controlled release of polypeptides
NZ246556A (en) * 1991-12-20 1996-03-26 Novo Nordisk As Pharmaceutical composition of a growth hormone and histidine
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
DK0955062T3 (da) * 1992-07-31 2007-09-17 Genentech Inc Vandig formulering indeholdende humant væksthormon
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation

Also Published As

Publication number Publication date
CZ145894A3 (en) 1994-12-15
JP3662580B2 (ja) 2005-06-22
RO112086B1 (ro) 1997-05-30
CA2125856A1 (en) 1993-07-08
DE69228704T2 (de) 1999-09-16
US5977069A (en) 1999-11-02
EP0618806A1 (en) 1994-10-12
DK204791D0 (da) 1991-12-20
RU94045921A (ru) 1996-08-27
US5851992A (en) 1998-12-22
WO1993012811A1 (en) 1993-07-08
FI942905A0 (fi) 1994-06-17
ATE177645T1 (de) 1999-04-15
BG98804A (bg) 1995-02-28
HU9401831D0 (en) 1994-09-28
EP0618806B1 (en) 1999-03-17
HUT69682A (en) 1995-09-28
CZ282826B6 (cs) 1997-10-15
DE69228704D1 (de) 1999-04-22
NZ246555A (en) 1996-03-26
KR100270726B1 (ko) 2000-11-01
KR940703689A (ko) 1994-12-12
AU3344593A (en) 1993-07-28
AU664416B2 (en) 1995-11-16
SK73794A3 (en) 1995-03-08
NO942299L (no) 1994-06-17
NO942299D0 (no) 1994-06-17
RU2098130C1 (ru) 1997-12-10
JPH07502515A (ja) 1995-03-16

Similar Documents

Publication Publication Date Title
FI942905A0 (fi) Stabiloitu kasvuhormonia ja asparagiinia sisältävä farmaseuttinen formulointi
FI942906A (fi) Kasvuhormonia ja histidiiniä sisältävä stabiloitu farmaseuttinen formulointi
IL115590A (en) Pharmaceutical formulation comprising a growth hormone and isoleucine
PT785795E (pt) Composicao farmaceutica
IL115592A (en) Stabilized pharmaceutical formulation comprising a growth hormone and leucine
NO884123D0 (no) Stabilisering av terapeutisk virksomme proteiner i farmasoeytiske preparater.
NO980103L (no) Stabilisert farmasöytisk preparat som omfatter et veksthormon og et peptid omfattende minst én basisk aminosyrerest og minst én sur aminosyrerest

Legal Events

Date Code Title Description
FD Application lapsed